Cellectis/$CLLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cellectis
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Ticker
$CLLS
Sector
Primary listing
Employees
219
Headquarters
Website
Cellectis Metrics
BasicAdvanced
$327M
-
-$0.60
3.03
-
Price and volume
Market cap
$327M
Beta
3.03
52-week high
$4.59
52-week low
$1.10
Average daily volume
146K
Financial strength
Current ratio
1.378
Quick ratio
0.533
Long term debt to equity
80.34
Total debt to equity
93.671
Interest coverage (TTM)
-5.80%
Profitability
EBITDA (TTM)
-33.038
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-93.00%
Operating margin (TTM)
-71.28%
Effective tax rate (TTM)
-0.78%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-7.43%
Return on equity (TTM)
-48.02%
Valuation
Price to revenue (TTM)
6.984
Price to book
2.9
Price to tangible book (TTM)
2.94
Price to free cash flow (TTM)
-12.107
Free cash flow yield (TTM)
-8.26%
Free cash flow per share (TTM)
-0.365
Growth
Revenue change (TTM)
223.09%
Earnings per share change (TTM)
-46.54%
3-year revenue growth (CAGR)
149.86%
10-year revenue growth (CAGR)
4.93%
3-year earnings per share growth (CAGR)
-37.90%
10-year earnings per share growth (CAGR)
6.30%
What the Analysts think about Cellectis
Analyst ratings (Buy, Hold, Sell) for Cellectis stock.
Bulls say / Bears say
Cellectis completed end-of-Phase 1 meetings with FDA and EMA for lasme-cel (UCART22) in July 2025, supporting the start of a pivotal Phase 2 trial in the second half of 2025 (GlobeNewswire)
The company held $230 million in cash, cash equivalents, and fixed-term deposits as of June 30, 2025, with funding to support clinical and manufacturing operations through the second half of 2027 (GlobeNewswire)
A strategic partnership with AstraZeneca covers three allogeneic CAR-T programs and an in vivo gene therapy project, providing non-dilutive funding and external validation of Cellectis’ platform (GlobeNewswire)
Key Phase 1 data for UCART22 and results for UCART20×22 are not anticipated until late 2025, pushing back the timeline for pivotal data that could help de-risk the stock in the near term (GlobeNewswire)
Cellectis is in arbitration with Servier regarding its CD19 license, with a tribunal decision expected by December 15, 2025; a negative decision could see Cellectis lose rights to key products and face significant compensation requirements (GlobeNewswire)
Factor Bioscience has filed a patent-infringement lawsuit in U.S. District Court, alleging Cellectis unlawfully used its mRNA/TALEN technology, which creates risks of legal costs and possible injunctions (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2025.
Cellectis Financial Performance
Revenues and expenses
Cellectis Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cellectis stock?
Cellectis (CLLS) has a market cap of $327M as of October 14, 2025.
What is the P/E ratio for Cellectis stock?
The price to earnings (P/E) ratio for Cellectis (CLLS) stock is 0 as of October 14, 2025.
Does Cellectis stock pay dividends?
No, Cellectis (CLLS) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Cellectis dividend payment date?
Cellectis (CLLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Cellectis?
Cellectis (CLLS) has a beta rating of 3.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.